证券之星消息，10月13日多元金融板块较上一交易日下跌0.62%，四川双马领跌。当日上证指数报收于 3889.5，下跌0.19%。深证成指报收于13231.47，下跌0.93%。多元金融板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 603300 | 海南华铁 | 8.15 | 3.95% | 461.06万 | 34.29 Z | | 000987 | 越秀资本 | 8.17 | 2.90% | 99.07万 | 8.10亿 | | 000958 | 电投产融 | 6.53 | 0.77% | 34.97万 | 2.26亿 | | 002961 | 瑞达期货 | 21.06 | 0.05% | - 4.64万 | 9614.01万 | | 600901 | 江苏金租 | 5.64 | 0.00% | 39.85万 | 2.23亿 | | 000617 | 中油资本 | 11.03 | -0.63% | 191.01万 | 20.88亿 | | 600927 | 永安期货 ...

Core Viewpoint - Sichuan Shuangma (000935.SZ) has announced its participation in a fund that invests in the GPU chip industry, with further details to be confirmed through public information [1] Group 1 - The company is involved in investments related to the GPU chip sector [1]

Group 1 - The core transaction involved Sichuan Shuangma, with a total of 120,000 shares traded on October 9, resulting in a transaction amount of 2.3652 million yuan, which accounted for 0.71% of the total trading volume for that day [1][2] - The transaction price was 19.71 yuan per share, representing an 11.54% discount compared to the market closing price of 22.28 yuan [1][2]

Core Insights - Sichuan Shuangma's stock increased by 5.09% to 22.51 CNY per share, with a trading volume of 206 million CNY and a turnover rate of 1.24%, resulting in a total market capitalization of 17.185 billion CNY [1] Company Overview - Sichuan Shuangma Co., Ltd. was established on October 20, 1998, and listed on August 24, 1999. The company is located in Chengdu, Sichuan Province, and operates primarily in the building materials industry and private equity fund investment management [1] - The revenue composition of Sichuan Shuangma includes: 33.36% from private equity fund management, 32.46% from cement, 23.08% from biomedicine, and 11.10% from aggregates [1] Fund Holdings - According to data, one fund under GF Fund has a significant holding in Sichuan Shuangma. The GF CSI Building Materials Index A Fund (004856) held 658,800 shares in the second quarter, accounting for 2.28% of the fund's net value, ranking as the tenth largest holding [2] - The GF CSI Building Materials Index A Fund was established on August 2, 2017, with a current size of 261 million CNY. Year-to-date returns are 5.32%, with a one-year return of 1.72%, and a cumulative loss of 5.93% since inception [2] Fund Manager Profile - The fund manager of GF CSI Building Materials Index A Fund is Lu Zhiming, who has a cumulative tenure of 14 years and 133 days. The total asset size under management is 24.629 billion CNY, with the best fund return during his tenure being 119.61% and the worst being -63.28% [3]

Group 1: Strategy Overview - The report emphasizes a transition towards a bull market, driven by recovering demand for physical assets amidst supply constraints, particularly in the copper market [3][9][12] - Recent disruptions in copper supply, notably from the Grasberg mine, are expected to create price elasticity for future manufacturing demand recovery [9][12] - The report highlights a shift from a focus on financial assets to physical assets, indicating a potential new cycle for resource commodities [4][12] Group 2: Key Companies and Industries - **Engineering Machinery: Hengli Hydraulic (601100.SH)** is positioned for growth due to increased overseas demand and domestic infrastructure projects, with a favorable outlook for its core business [14] - **Non-Banking Financial: Sichuan Shuangma (000935.SZ)** is transitioning to an innovative drug CDMO model, with significant growth potential from its investment projects and pharmaceutical capacity expansion [15][16] - **Food and Beverage: Angel Yeast (600298.SH)** is expected to benefit from overseas expansion and improved domestic demand, with a favorable cost environment [17] - **Transportation: Juneyao Airlines (603885.SH)** is set to gain from industry supply-demand improvements and reduced interest expenses, with positive short-term catalysts from seasonal demand [18] - **Retail: Gu Ming (1364.HK)** is leveraging a unique store expansion strategy in the competitive milk tea market, with significant growth potential in coffee products [19] - **Media and Internet: Tencent Holdings (0700.HK)** is integrating AI across its ecosystem, enhancing its competitive edge and driving growth through high-margin businesses [20][21] - **Electronics: Lante Optics (688127.SH)** is experiencing strong demand in various sectors, with supply constraints on production equipment [22] - **Computing: Hikvision (002415.SZ)** is seeing a recovery in operating quality and profitability, with a focus on AI-driven products [23] - **Pharmaceuticals: Innovent Biologics (9969.HK)** is a leader in hematology and autoimmune therapies, with significant growth potential from its core products [24] - **Defense and Military: Guobo Electronics (688375.SH)** is positioned to benefit from growth in military and satellite internet sectors, with a strong market outlook [25]

Core Viewpoint - Sichuan Shuangma's stock price has shown significant growth this year, with a year-to-date increase of 49.17%, indicating strong market performance and investor interest [1][2]. Financial Performance - For the first half of 2025, Sichuan Shuangma reported revenue of 629 million yuan, representing a year-on-year growth of 30.42% [2]. - The net profit attributable to shareholders for the same period was 129 million yuan, reflecting a year-on-year increase of 13.42% [2]. Stock Market Activity - As of September 25, Sichuan Shuangma's stock price was 21.60 yuan per share, with a market capitalization of 16.49 billion yuan [1]. - The stock experienced a decline of 2.04% on September 25, with a trading volume of approximately 75.28 million yuan and a turnover rate of 0.45% [1]. - The stock has seen a net outflow of 9.75 million yuan in principal funds, with significant selling pressure from large orders [1]. Shareholder Information - As of June 30, 2025, the number of shareholders increased to 30,900, with an average of 24,706 circulating shares per shareholder, a slight decrease of 0.72% [2][3]. - The company has distributed a total of 931 million yuan in dividends since its A-share listing, with 259 million yuan distributed in the last three years [3]. Business Segments - Sichuan Shuangma's main business segments include private equity fund management (33.36%), cement production (32.46%), biomedicine (23.08%), and aggregates (11.10%) [1]. - The company operates within the non-banking financial sector, specifically in diversified finance and asset management [1]. Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited was the ninth largest circulating shareholder, holding 3.6282 million shares, a decrease of 326,100 shares from the previous period [3].

Market Overview - The diversified financial sector experienced a decline of 1.56% on September 24, with Lakala leading the drop [1] - The Shanghai Composite Index closed at 3853.64, up 0.83%, while the Shenzhen Component Index closed at 13356.14, up 1.8% [1] Stock Performance - Notable gainers in the diversified financial sector included Sichuan Shuangma, which rose by 4.65% to a closing price of 22.05, and Yalian Development, which increased by 4.52% to 5.32 [1] - Lakala, on the other hand, saw a decrease of 2.05%, closing at 23.93, with a trading volume of 483,300 shares and a transaction value of 1.156 billion [2] Capital Flow - The diversified financial sector saw a net outflow of 118 million from institutional investors, while retail investors contributed a net inflow of 191 million [2][3] - Among individual stocks, Zhongliang Capital had a net inflow of 60.1 million from institutional investors, while it experienced a net outflow of 34.3 million from retail investors [3]

Core Points - Sichuan Shuangma announced that its subsidiary Hubei Jianxiang Biopharmaceutical Co., Ltd. successfully passed an on-site inspection by the Russian Federal Ministry of Industry and Trade's drug inspection authority from July 30 to August 1, 2025 [2] - The company received the Good Manufacturing Practice (GMP) certificate from the Russian Federal Ministry of Industry and Trade, confirming compliance with the Eurasian Economic Union's pharmaceutical production standards [2]

Group 1 - Xinxiang Chemical Fiber will suspend production for approximately 90 days starting October 1, 2025, affecting an annual capacity of 31,200 tons, resulting in a revenue decrease of approximately 185 million yuan and a profit reduction of about 48 million yuan [1] - Bozhong Precision plans to transfer 18.29% of its stake in Suzhou Linghou Robot for 64 million yuan, retaining a 21.61% ownership post-transaction [1] - Haixing Electric is a recommended candidate for a State Grid procurement project, with an expected bid amount of approximately 128 million yuan [2] Group 2 - Samsung Medical is a recommended candidate for multiple State Grid procurement projects, with a total expected bid amount of approximately 193 million yuan [2][3] - Youxunda is a recommended candidate for a State Grid procurement project, with a bid amount of approximately 107 million yuan, representing 10.55% of its 2024 revenue [3] - Tiancheng Self-Control has received a notification for a seat assembly project from a well-known domestic new energy vehicle company, expected to start mass production in June 2026 [4] Group 3 - YKYY013 injection has received FDA approval for clinical trials to treat chronic hepatitis B virus infection [4] - Pulaide has signed a strategic cooperation agreement with an international electric tool brand, with a total procurement amount exceeding 700 million yuan over five years [4] - Sichuan Shuangma's subsidiary has obtained GMP certification from Russia, covering core aspects of drug quality and production systems [6] Group 4 - Boshi Co. has signed an industrial service contract worth approximately 96.99 million yuan with Guoneng Baotou Coal Chemical [7] - Wansheng Intelligent is a recommended candidate for a State Grid project, with an expected bid amount of approximately 67.98 million yuan, representing 7.25% of its 2024 revenue [9][10] - Huazi Industrial plans to sell its dairy farm assets for 38.5 million yuan, expecting a positive impact of approximately 11.7 million yuan on its current profits [10] Group 5 - Jinguang Electric has won a State Grid project with a total bid amount of approximately 28.4 million yuan, accounting for 3.82% of its 2024 revenue [11] - Nanjiao Food reported a net profit of 10,410 yuan for August, a year-on-year decrease of 98.31% [13] - Dongfang Bio's subsidiary has obtained registration certificates for two medical device products [15] Group 6 - Lanhua Kecai has signed a strategic cooperation agreement with Shanghai Pangu Power to promote intelligent and efficient transformation in the coal mining industry [17] - Yabao Pharmaceutical has decided to terminate the SY-009 research project, with a total investment of approximately 87.87 million yuan to be fully impaired [18] - Tian Shili's subsidiary has received approval for a new indication for its recombinant human urokinase injection for acute ischemic stroke treatment [20] Group 7 - Su Yan Jingshen's executives plan to increase their shareholding in the company, with a total investment of between 1.9 million and 2.66 million yuan [22] - Baiyun Electric and its subsidiary have won a State Grid project with a total bid amount of approximately 162 million yuan, covering multiple equipment types [23] - China West Electric's director has resigned due to work reasons, effective September 19, 2025 [25] Group 8 - Jianan Intelligent is a recommended candidate for a State Grid project with a total expected bid amount of approximately 73.12 million yuan [26] - Juhua Technology is a recommended candidate for a State Grid project with a total expected bid amount of approximately 142 million yuan [27] - Tengyuan Cobalt's actual controller has committed not to reduce holdings for the next 12 months, holding 37.89% of the total shares [28] Group 9 - Changfei Optical Fiber announced that Draka Comteq B.V. no longer holds H shares in the company after selling 37.59 million shares [28] - Mongcao Ecological's subsidiary has signed a contract for an ecological restoration project worth 225.2 million yuan [29] - Weiao Co. plans to distribute a cash dividend of 0.1 yuan per share, totaling approximately 39.29 million yuan [30]

Core Viewpoint - Sichuan Shuangma (000935.SZ) announced that its subsidiary Hubei Jianxiang Biopharmaceutical Co., Ltd. successfully passed an on-site inspection by the Russian Federal Service for Surveillance in Healthcare, receiving the GMP certificate from the Eurasian Economic Union, which enhances its competitiveness in the active pharmaceutical ingredient market and supports the promotion of Teriparatide in the region [1] Group 1 - Hubei Jianxiang underwent an inspection from July 30 to August 1, 2025, by the Russian Federal Ministry of Industry and Trade's drug inspection agency [1] - The company received the GMP certificate, confirming compliance with the quality system for active pharmaceutical ingredient production recognized by Russia and the Eurasian Economic Union [1] - The certification validates the maturity of Hubei Jianxiang's production control, quality management, and public system assurance, strengthening its core competitiveness in the active pharmaceutical ingredient sector [1] Group 2 - The GMP certification provides essential qualification support for the market promotion of Teriparatide active pharmaceutical ingredients in the region [1] - This achievement is expected to enhance the company's influence in international markets and positively contribute to future operational performance growth [1]